Latest Commercialisation News

Page 7 of 239
Parkway Corporate delivered record quarterly revenue of $7.71 million and $1.08 million in operating cash flow as its mine dewatering contract expanded to about $2.1 million. The company also advanced its Queensland brine project, although its next test is turning approvals and technology development into funded commercial infrastructure.
Victor Sage
Victor Sage
30 Oct 2026
Blue Star Helium has recorded its first commercial helium sales from the Pinon Canyon plant in Colorado, delivering five tube trailers during the September quarter. The milestone comes with an extended offtake agreement through March 2027, but production growth still depends on permits, well development and funding.
Victor Sage
Victor Sage
30 Oct 2026
Metallium has moved its Texas processing strategy closer to commercial testing, recording its first US$500,000 technology-services payment and preliminary PCB recoveries above 90%. The next proof point is whether those results can survive commissioning, product qualification and the funding demands of an 8,000-tonne-per-year operation.
Victor Sage
Victor Sage
30 Oct 2026
Papyrus Australia says its second production-scale board run delivered significantly improved internal test results, with samples now sent to TBS for acceptance testing. The progress is tempered by a reported $365,000 cash balance, $447,000 in unused facilities and estimated funding for just 1.51 quarters.
Victor Sage
Victor Sage
30 Oct 2026
Hydrix reported September-quarter revenue growth of 11.6% year on year and secured further medical and Defence milestones. But with $1.5 million in cash and reported funding covering only 1.30 quarters, the company still needs contract wins to convert into receipts and revenue.
Sophie Babbage
Sophie Babbage
29 Oct 2026
Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.
Victor Sage
Victor Sage
29 Oct 2026
1414 Degrees has sharpened the commercial case for its Aurora precinct, signing a pathway agreement for up to 1 GW of AI data centre infrastructure and attracting potential partners for a A$350 million to A$550 million first-stage energy project. Its SiNTL battery material also showed sustained performance over more than 640 cycles, although both programs remain some distance from binding commercial revenue.
Victor Sage
Victor Sage
29 Oct 2026
Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.
Ada Torres
Ada Torres
29 Oct 2026
Adisyn has identified graphene at all 12 sampled locations on a full 200mm wafer, moving its low-temperature deposition platform beyond 1cm² laboratory coupons. The ASX-listed technology company ended September with A$14.4 million in cash and no debt, but commercial qualification remains ahead.
Sophie Babbage
Sophie Babbage
29 Oct 2026
AnteoTech reported a quarter of technical milestones and commercial discussions across its battery and life sciences businesses, including new agreements with Xerabrid and Airspeeder. The company ended September with about A$11 million in cash, although an inconsistency in the Appendix 4C reconciliation needs clarification.
Victor Sage
Victor Sage
29 Oct 2026
InFocus has reduced quarterly operating cash outflow by 40% while advancing Codexa and securing a conditional first customer for its overseas real-money gaming platform. The USD 2.4 million minimum fee commitment is substantial for the company, but it depends on development, licensing and launch milestones that have not yet been completed.
Sophie Babbage
Sophie Babbage
29 Oct 2026
BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.
Victor Sage
Victor Sage
29 Oct 2026

Browse the archive

Full archive